Takeda Files NDA For Fixed-Dose Combination Tablet Of Actos With Sulfonylurea In Japan
Combination tablet, for the treatment of type 2 diabetes
Takeda has filed a New Drug Application (NDA) to the Japanese Ministry of Health, Labour and Welfare, for a fixed-dose combination tablet of Actos with sulfonylurea. The drug is intended for the treatment of type 2 diabetes.
A fixed-dose combination tablet of Actos with sulfonylurea was approved under the brand name - Duetact in the US in July 2006. It was approved under the brand name of Tandemact in the EU in January 2007.
Nancy Joseph-Ridge, general manager, Pharmaceutical Development Division of Takeda, said: “Since there are also many cases where Actos and sulfonylurea are administered in combination in Japan, we are expecting that a fixed-dose combination tablet of Actos with sulfonylurea, if approved, will positively contribute to the treatment of Japanese patients with diabetes as well.”
Related Insight
Suppliers Directory
Garvens - Pharmaceutical Checkweighing and Serialisation Solution Provider
Mettler-Toledo Garvens GmbH has been a member of the METTLER TOLEDO group since 1986 and is one of the world's leading manufacturers of pharmaceutical dynamic weighing systems with a strong focus on the fulfilment of customer needs.
Suppliers
TBM Consulting Group - Lean Sigma Manufacturing Services
The global fallout from the real estate and banking crisis has impacted economies worldwide since 2009 and is likely to carry over well into 2012. The drop in consumer demand, capital spending cuts, layoffs, rising unemployment, the spectre of inflation and erratic equity markets has put intense pressure on margins and heightened everyone’s focus on cutting costs.
Suppliers
PDP Couriers - The Global Clinical Trials And Healthcare Specialist
With over 18 years experience PDP is a key specialist Courier company providing global solution-led logistics support services to Contract Research Organizations, Biopharmaceutical Companies and the Healthcare industry.
Suppliers
Hapa - Late Stage Customisation and On Demand Printing Technologies
Hapa is the world leader in late stage customisation and on demand printing technologies for the pharmaceutical sector, delivering fast, accurate and value-creating packaging solutions.
Suppliers
Production & Manufacturing
Fine & Speciality Chemicals
Manufacturing
Process & Production
OTC
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Drug Research Drug Delivery Drug Discovery & Development
Contract Research & Services Clinical Trials Contract Research Contract Services
Automation IT & Software Laboratory Instrumentation
Inward Investment Packaging Regulatory Affairs
Intelligence
Reagents for Fine Organic Synthesis – Building Blocks
Published by Enamine
White Papers
An Interview with Paul Gerteis
Published by Gerteis
White Papers
PolarFit™ Ultra-Fine-Grinding Mill
Published by Air Products
White Papers
The Devil is in the Detail!
Published by Vaisala
White Papers
Buy the latest industry research online today!
Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
GBI Research, the leading business intelligence provider, has released its latest report, “Nanotechnology in Drug Delivery - Technological Improvements and Novel Approaches to Fulfill High Potential” that provides key data, information and analysis of the major trends and issues affecting the global nano-enabled drug delivery market. The report provides a comprehensive insight into the current and future application of nanotechnology in the drug delivery systems. It also provides an insight into the key drivers and barriers for the market growth. The report also provides a detailed analysis of the trends and its effects on the nano-enabled drug delivery market. The report also talks about the key regulations that affect the nanotechnology research and development and issues related to its use in pharmaceutical market. The report also details some case study of the latest technology being exploited in pharmaceutical industry. The report also provides detailed analysis of major deals that have happened in the nano-enabled drug delivery market landscape. At the end, the report looks into the future players. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GBI Research’s team of industry experts. The nano-enabled drug delivery market has been a high growth market and expected to grow at a faster rate in the near future. According to a study conducted by Willi Paul, and Chandra P. Sharma, the nano-enabled drug delivery market was $1.7 billion in 2009 and expected to reach over $4.8 billion in 2012. The market will witness increased competition, high investment from venture capitalist and government. The M&A and Licensing landscape will see significant changes in the coming future. This is because market is expected to become more lucrative in coming future. The major drivers for the market growth are Increasing acceptance of nano-enabled drugs, and a strong pipeline portfolio. The increasing governmental funding and R&D interest will strengthen the market in future. However, lack of consistent policy on technology transfer, poor R&D facility, and tight audit control and lack of centralized system will restrain the market growth. The nano-enabled drug delivery market has strong pipeline. The pipeline is primarily dominated by molecules in early stage of development. This suggests that the there is high level of R&D investment. This will support the future market and will fuel the licensing activity. Reports Buy online from $3500
Comments may be moderated for spam, obscenities or defamation.